Are peptide conjugates the golden therapy against obesity?
| Autor: | Timo D. Müller, M. H. Tschöp, Maximilian Kleinert, Sara J. Brandt |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
obesity medicine.medical_specialty Endocrinology Diabetes and Metabolism Bariatric Surgery Diabetes Metabolism Obesity Peptides 030209 endocrinology & metabolism Review Bioinformatics 03 medical and health sciences 0302 clinical medicine Endocrinology Weight loss Single entity Diabetes mellitus Internal medicine Drug Discovery Lifestyle intervention medicine Animals Humans Life Style Beneficial effects diabetes business.industry medicine.disease Exercise Therapy ddc 3. Good health Weight Reduction Programs Clinical trial 030104 developmental biology peptides Anti-Obesity Agents medicine.symptom Energy Metabolism business metabolism Hormone |
| Zdroj: | Journal of Endocrinology J. Endocrinol. 238, R109-R119 (2018) The Journal of Endocrinology |
| ISSN: | 1479-6805 0022-0795 |
| DOI: | 10.1530/joe-18-0264 |
| Popis: | Obesity is a worldwide pandemic, which can be fatal for the most extremely affected individuals. Lifestyle interventions such as diet and exercise are largely ineffective and current anti-obesity medications offer little in the way of significant or sustained weight loss. Bariatric surgery is effective, but largely restricted to only a small subset of extremely obese patients. While the hormonal factors mediating sustained weight loss and remission of diabetes by bariatric surgery remain elusive, a new class of polypharmacological drugs shows potential to shrink the gap in efficacy between a surgery and pharmacology. In essence, this new class of drugs combines the beneficial effects of several independent hormones into a single entity, thereby combining their metabolic efficacy to improve systems metabolism. Such unimolecular drugs include single molecules with agonism at the receptors for glucagon, glucagon-like peptide 1 and the glucose-dependent insulinotropic polypeptide. In preclinical studies, these specially tailored multiagonists outperform both their mono-agonist components and current best in class anti-obesity medications. While clinical trials and vigorous safety analyses are ongoing, these drugs are poised to have a transformative effect in anti-obesity therapy and might hopefully lead the way to a new era in weight-loss pharmacology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|